These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 25878791)
1. Dry powder inhalers and the right things to remember: a concept review. Dal Negro RW Multidiscip Respir Med; 2015; 10(1):13. PubMed ID: 25878791 [TBL] [Abstract][Full Text] [Related]
2. The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates. Clark AR; Weers JG; Dhand R J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):1-11. PubMed ID: 31613682 [TBL] [Abstract][Full Text] [Related]
3. The contribution of patients' lung function to the inspiratory airflow rate achievable through a DPIs' simulator reproducing different intrinsic resistance rates. Dal Negro RW; Turco P; Povero M Multidiscip Respir Med; 2021 Jan; 16(1):752. PubMed ID: 33953914 [TBL] [Abstract][Full Text] [Related]
4. Prerequisites for a dry powder inhaler for children with cystic fibrosis. Lexmond AJ; Hagedoorn P; Frijlink HW; Rottier BL; de Boer AH PLoS One; 2017; 12(8):e0183130. PubMed ID: 28800360 [TBL] [Abstract][Full Text] [Related]
5. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease. Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254 [TBL] [Abstract][Full Text] [Related]
6. Lung Function Can Predict the Expected Inspiratory Airflow Rate through Dry Powder Inhalers in Asthmatic Adolescents. Dal Negro RW; Turco P; Povero M Children (Basel); 2022 Mar; 9(3):. PubMed ID: 35327749 [TBL] [Abstract][Full Text] [Related]
7. The clinical relevance of dry powder inhaler performance for drug delivery. Demoly P; Hagedoorn P; de Boer AH; Frijlink HW Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253 [TBL] [Abstract][Full Text] [Related]
8. Effect of inhaler design variables on paediatric use of dry powder inhalers. Lexmond AJ; Kruizinga TJ; Hagedoorn P; Rottier BL; Frijlink HW; de Boer AH PLoS One; 2014; 9(6):e99304. PubMed ID: 24901338 [TBL] [Abstract][Full Text] [Related]
9. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. Tiddens HA; Geller DE; Challoner P; Speirs RJ; Kesser KC; Overbeek SE; Humble D; Shrewsbury SB; Standaert TA J Aerosol Med; 2006; 19(4):456-65. PubMed ID: 17196074 [TBL] [Abstract][Full Text] [Related]
10. Lung characteristics in elderly males and females patients with COPD: differences and optimal use of dry powder inhalers (DPIs). Terzano C; Oriolo F Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2708-2716. PubMed ID: 28678314 [TBL] [Abstract][Full Text] [Related]
11. The inhalation characteristics of patients when they use different dry powder inhalers. Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999 [TBL] [Abstract][Full Text] [Related]
12. [Peak inspiratory flow generated through different analogue dry powder inhalers in Shenzhen healthy preschool children]. Zhang QL; Zheng JP; Pan WH; He H; Chen GL; An JY; Yuan LF; Luo DF Zhonghua Er Ke Za Zhi; 2008 Feb; 46(2):98-103. PubMed ID: 19099680 [TBL] [Abstract][Full Text] [Related]
13. Successful use of DPI systems in asthmatic patients--key parameters. Richter K Respir Med; 2004 Oct; 98 Suppl B():S22-7. PubMed ID: 15481285 [TBL] [Abstract][Full Text] [Related]
14. Clarifying the dilemmas about inhalation techniques for dry powder inhalers: integrating science with clinical practice. Azouz W; Chrystyn H Prim Care Respir J; 2012 Jun; 21(2):208-13. PubMed ID: 22336894 [TBL] [Abstract][Full Text] [Related]
15. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers. Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848 [TBL] [Abstract][Full Text] [Related]
16. Novolizer: how does it fit into inhalation therapy? Magnussen H Curr Med Res Opin; 2005; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944 [TBL] [Abstract][Full Text] [Related]
17. Dry-powder inhalers in patients with persistent airflow limitation: usability and preference. Dal Negro RW; Povero M Multidiscip Respir Med; 2016; 11(1):31. PubMed ID: 27597888 [TBL] [Abstract][Full Text] [Related]
18. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers. Ghosh S; Ohar JA; Drummond MB J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):381-387. PubMed ID: 28933581 [TBL] [Abstract][Full Text] [Related]
19. The Novolizer: overcoming inherent problems of dry powder inhalers. Kohler D Respir Med; 2004 Apr; 98 Suppl A():S17-21. PubMed ID: 15139564 [TBL] [Abstract][Full Text] [Related]
20. [The relationship between inspiratory pressure and flow through dry powder inhaler available in Japan]. Kondo T; Tanigaki T; Tazaki G; Watanabe H; Ishii H; Tsunoda T; Uruma T Arerugi; 2010 Aug; 59(8):950-5. PubMed ID: 20820136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]